1 / 47

Research: State of the Art

Research: State of the Art. Professor Derek Pheby. Where are we starting from? (1). What we know: ME is a syndrome (defined by its symptoms, not underlying pathology) Characterised by multi-system dysfunction Varies in severity and duration Acute or insidious onset

kamali
Download Presentation

Research: State of the Art

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Research: State of the Art Professor Derek Pheby

  2. Where are we starting from? (1) What we know: • ME is a syndrome (defined by its symptoms, not underlying pathology) • Characterised by multi-system dysfunction • Varies in severity and duration • Acute or insidious onset • Range of trigger factors, frequently viral • Most common in women, particularly young adults (though occurs at all ages)

  3. Where are we starting from? (2) What we don’t know • Underlying pathology – one disease or several? • How to treat it

  4. Where are we starting from? (3) Common myths: • It doesn’t exist! • If it does exist, it’s a psychological condition • NICE has had the last word on the subject • Graded exercise and cognitive behaviour therapy are effective treatments

  5. The Pathophysiology of ME –Cause or Effect? • Hypothalamic-pituitary dysfunction • Neuromuscular abnormalities • Abnormal serum cortisol • Abnormal patterns of cytokine expression • Abnormal patterns of gene expression • Mitochondrial dysfunction • Oxidative stress

  6. Research Activity (1) Published scientific papers: • US 50% • UK 30% • Rest of world 20% - but it doesn’t really amount to a coherent corpus of scientific knowledge

  7. Research Activity (2) Why has all this work not advanced knowledge further? • Vicissitudes of funding • No coherent strategy • No supportive infrastructure

  8. The Observatory project (1) • Funded for three years by the Big Lottery Fund • Sponsored by Action for ME • Academic collaboration of three universities: • London School of Hygiene and Tropical Medicine • University of Hull • University of East Anglia

  9. The Observatory project (2) Purpose: • Fill gaps in knowledge • Epidemiology • Qualitative social research • Create range of infrastructure facilities to support research

  10. The Observatory project (3) Output to date: • Six scientific papers published • Disease Register • Services Directory

  11. The Observatory project (4) New projects: • Biobank • Post Mortem tissue archive

  12. The Biobank Aims : • To develop a key resource for biomedical research, especially the investigation of biomarkers for diagnosis and prognosis.

  13. The Biobank (2) Specific main objectives: • to establish a biobank for the study of ME/CFS, as a resource for high quality and ethically approved biomedical research studies benefiting from well catalogued blood samples, which are linkable to clinical and risk factors data; • to investigate risk factors for severity; • to correlate clinical phenotype with disease severity.

  14. The Biobank (3) Subsequently: • to disseminate the resource to the research community • to plan high throughput studies, benefiting from sample collections and rapid advancing sequencing (e.g. whole genome sequencing,) and other molecular techniques, such as those investigating immune and genetic biomarkers • to link the Biobank to the planned ‘post-mortem’ tissue bank for the study of ME/CFS.

  15. The Biobank (4) Outcomes • full implementation of the ME/CFS Biobank, including: • recruitment of well characterised cases with ME/CFS and controls, • blood sample collections and storage.

  16. The Biobank (5) Other Research Possibilities • Linkage of data from stored biological samples with longitudinal clinical data from the Disease Register will enable identification of clinical and pathological factors associated with particular adverse outcomes of interest. • e.g. what clinical and pathological factors may be associated with disease severity? • This will contribute to the development of prevention strategies

  17. The Biobank (6) • $1.5 million awarded by National Institutes of Health, Washington DC • Making possible a very large increase in the scale of the project

  18. The Biobank (7): The NIH Project Aims (i) • to investigate risk factors for disease severity; • to correlate clinical phenotype with disease severity; • to disseminate the resource to researchers and others • to plan high throughput studies.

  19. The Biobank (8): The NIH Project Aims (ii) High throughput studies will benefit from:- • sample collections; • rapidly advancing molecular techniques, e.g. investigating immune and genetic biomarkers; • expansion of the Disease Register; • link to post-mortem tissue bank for the study of ME/CFS.

  20. More Information • http://www.lshtm.ac.uk/itd/crd/ research/cure-me/index.html

  21. Post Mortem Tissue Archive – Pros & Cons Rationale • To create an opportunity to study neurological and other tissues from people with ME, in order to investigate underlying disease processes. • Post mortem tissue archives have been established and function effectively in other neurodegenerative diseases, and one for ME exists in the US

  22. Post Mortem Tissue Archive – Pros & Cons Problems • Logistics of specimen handling • Cost • Time

  23. Post Mortem Tissue Archive – Feasibility Study • ME has rarely been studied in post-mortem examinations, despite evidence of abnormalities from neuroimaging. • Aim: To ascertain the feasibility of developing a national post-mortem ME/CFS tissue bank in the UK. • Method: Case study, involving key informant interviews, focus group of PWME, workshop with experts • Results suggested that post-mortem tissue bank was desirable, feasible, and acceptable to possible donors. • Lacerda EM, Nacul L, Pheby D, Shepherd C, Spencer P. Exploring the feasibility of establishing a disease-specific post-mortem tissue bank in the UK: a case study in ME/CFS. J Clin Pathol (2010); 63: 1032-1034.

  24. Other Initiatives: • MRC • Euromene • US Department of Defense

  25. The MRC Initiative • £1.6 million allocated, following work of Expert Group, for call entitled: • “Understanding the Mechanisms of CFS/ME” • Closing date 7 June 2011.

  26. MRC (2) - Aims • Support high-quality, innovative research that increases the CFS/ME knowledge base; • Address the mechanisms underlying chronic changes in CFS/ME, particularly: • Autonomic dysfunction • Cognitive symptoms • Fatigue • Immune dysregulation • Pain • Sleep disorders

  27. MRC (3) – Aims (continued) • Enhance understanding through study of cross-disease symptomology • Address lack of capacity in CFS/ME research, and need for multidisciplinary teams • Involve partnerships between CFS/ME researchers and leading investigators in other fields.

  28. MRC (4) - The Five Funded Projects • Identifying the biological fingerprints of fatigue Dr Wan Ng, Newcastle University • Understanding the pathogenesis of autonomic dysfunction in chronic fatigue syndrome and its relationship with cognitive impairment Professor Julia Newton , Newcastle University • Modulation of aberrant mitochondrial function and cytokine production in skeletal muscle of patients with CFS by supplementary polyphenols Professor Anne McArdle, Universities of Liverpool & Leeds • Can enhancing slow wave sleep SWS improve daytime function in patients with CFS? Professor David Nutt, Imperial College London • Persistent fatigue induced by interferon-alpha: a new immunological model for chronic fatigue syndrome Dr Carmine Pariante, King’s College London

  29. MRC (5) - Identifying the biological fingerprints of fatigue • Aims: • To improve understanding of the mechanisms of fatigue by: • analysing the immune systems of > 500 patients with primary Sjögren syndrome • identifying immune system abnormalities in these patients • in order to help identify the “biological fingerprints” of fatigue, hopefully leading to: • new treatments. • a clinical diagnostic test for CFS/ME.

  30. MRC (6) - Understanding the pathogenesis of autonomic dysfunction in CFS and its relationship with cognitive impairment • Aims: • To explore the causes of autonomic nervous system dysfunction (→ dizziness and light-headedness in 90% of PWME), • using fMRI to measure changes in brain blood flow to the brain • relating this to cognition and nervous system dysfunction, in order to lay the foundations for: • new diagnostic tools • better understanding of nervous system abnormalities • development of targeted treatments

  31. MRC (7) Modulation of aberrant mitochondrial function and cytokine production in skeletal muscle of patients with CFS by supplementary polyphenols • Aim: • To use a newly-developed technique to study muscle mitochondria, in order to: • learn more about how CFS/ME develops and becomes chronic

  32. MRC (8) - Can enhancing slow wave sleep improve daytime function in patients with CFS? Aims: • To study sleep disturbance in CFS/ME. • To measure the effect of drug-induced deep restorative sleep in CFS/ME patients on brain function while awake. • To increase understanding of the impact of sleep disturbance CFS/ME sufferers, in order to develop new treatments.

  33. MRC (9) - Persistent fatigue induced by interferon-alpha: a new immunological model for CFS Aims: • To study patients undergoing IFN-alpha treatment for Hepatitis C [NB IFN-alpha induces fatigue] • To identify resultant biological changes, hopefully leading to: • a check-list of blood measures to predict who will develop CFS/ME • identification of new targets for therapy.

  34. MRC (10) - Conclusions • Common Themes: • Analogies with other illnesses • Start with symptoms • Explore underlying disease mechanisms • Based on improved understanding of pathology, develop new diagnostic tests &/or treatments

  35. EUROMENE • 30+ participating centres in 15 countries; • Just submitted proposal to EU for €6 million to support collaborative research as part of the Horizon 2020 programme; • Title: “Understanding ME/CFS: elucidating determinants, risk factors and pathways, in order to develop personalised preventive, diagnostic and therapeutic strategies”

  36. EUROMENE (2): Aims of the proposed project Increasing understanding of ME/CFS by:- • mapping knowledge in a systems medicine model, enriched with novel nanoanalytical, new generation sequencing, proteome analysis data, and PET studies; • developing an integrated translational platform incorporating new and existing knowledge, and well characterised patient cohorts in seven EU countries; • leading to new diagnostic and therapeutic products, and optimal prevention and treatment strategies.

  37. Rituximab (1) • A monoclonal antibody against the protein CD20, found on the surface of B lymphocytes. Function • Rituximab destroys normal and malignant B cells that have CD20 on their surfaces.

  38. Rituximab (2) Uses • To treat diseases with excessive numbers, overactive or dysfunctional B cells, e.g. leukaemias, lymphomas, including Hodgkin's disease, also autoimmune diseases, e.g. rheumatoid arthritis, lupus, autoimmune haemolytic anaemia, in patients not responding to anti-TNF-alpha therapy.

  39. Rituximab (3) – Pilot Study • A CFS patient undergoing chemotherapy for Hodgkin's disease experienced transient CFS recovery, thought to be related to methotrexate, which induces immunomodulation partly through B-cell depletion. • Subsequently, this patient and two others were B-cell depleted by rituximab infusion • All three showed improvement of all CFS symptoms. • Fluge O., Mella O. Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: A preliminary case series. 2009 BMC Neurology 9

  40. Red Herrings! • PACE • XMRV

  41. PACE: Definitely not the last word (1) Significant weaknesses admitted: • Only studied people with mild and moderate illness: • Oxford case definition • Extended criteria to improve recruitment • “Standard medical care” inadequate. • No objective or consistent outcome assessment

  42. PACE: Definitely not the last word (2) Other weaknesses: • Intention to treat analysis poorly applied • Exaggerated claims regarding outcomes • Improvements marginal for all therapies • Many showed no improvement • However, adverse consequences were rare.

  43. XenotropicMurineLeukemia Virus–Related Virus (XMRV) • 2009: Lombardi et al (Whittemore-Peterson Institute University of Nevada, Reno, NV) report XMRV, a gammaretrovirus in 67% of patients (67%) compared to 3.7% of healthy controls. • Numerous subsequent studies fail to replicate this finding • Meanwhile, Mikovits et al (Whittemore-Peterson Institute) cast doubt on their own analyses. • Consensus emerges that DNA or RNA contamination of test kits is very likely.

  44. Action for ME Pilot Studies (May 2012) • Dr Phil Manning and Prof Julia Newton, Newcastle University. Understanding muscle dysfunction in M.E./CFS: developing a drug pre-testing system • Dr Jason Ellis, Northumbria University: A case controlled study exploring the qualitative experience of sleep, the roles of sleep architecture and diurnal patterns of salivary cortisol in M.E./CFS • Prof Annalena Venneri, University of Sheffield:Uncovering the biological correlates of cognitive impairment associated with fatigue in M.E./ CFS: a pilot study of cognition and functional connectivity pre and post-exertional malaise.

  45. What next for ME research?

  46. Thank you for listening • Any questions, or points for discussion?

  47. Chronic Fatigue Syndrome Research Foundation CFS/ME Research Collaborative

More Related